BCL2L12

Across TCGA pan-cancer cohorts, BCL2L12 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCL2L12 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher BCL2L12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCL2L12 expression acts as an unfavorable survival marker.

CESC, SARC, and SKCM are the cancer types where BCL2L12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.209	0.745	<.001	36	view →
SARC	OS	Median	All	0.109	0.827	<.001	9	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BRCA	OS	Median	All	0.181	0.579	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BCL2L12–CESC (DFS)

Open the CESC breakdown →